Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBT (2018 - 2025)

Historic EBT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' EBT fell 8887.64% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 693.97%. This contributed to the annual value of -$80.9 million for FY2024, which is 19022.95% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' EBT stood at -$13.4 million, which was down 8887.64% from -$9.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year EBT high stood at $118.6 million for Q4 2022, and its period low was -$57.7 million during Q1 2021.
  • For the 5-year period, Arcturus Therapeutics Holdings' EBT averaged around -$17.8 million, with its median value being -$21.6 million (2022).
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' EBT tumbled by 50944.83% in 2021, and later surged by 41516.0% in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' EBT stood at -$37.6 million in 2021, then surged by 415.16% to $118.6 million in 2022, then plummeted by 109.65% to -$11.4 million in 2023, then crashed by 162.2% to -$30.0 million in 2024, then soared by 55.19% to -$13.4 million in 2025.
  • Its EBT stands at -$13.4 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$14.1 million for Q1 2025.